Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 1/20 | 0.56 |
| ▸ | EP300 | Q09472 | 1/20 | 0.56 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.56 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 11/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA3 | P07451 | 1/20 | 0.49 |
| ▸ | CD40 | P25942 | 1/20 | 0.45 |
| ▸ | CD40LG | P29965 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5000592 | 1.00 | PRMT3 (0.56) | PRMT3EP300PRMT6PRMT1ENPP2 | |
| SCHEMBL29660624 | 1.00 | PRMT3 (0.56) | PRMT3EP300PRMT6PRMT1ENPP2 | |
| SCHEMBL13880631 | 0.94 | PRMT1 (0.64) | PRMT3EP300PRMT6PRMT1ENPP2 | |
| SCHEMBL14529309 | 0.92 | PRMT3 (0.58) | PRMT3EP300PRMT6PRMT1ENPP2 | |
| SCHEMBL13880628 | 0.92 | PRMT3 (0.58) | PRMT3EP300PRMT6PRMT1ENPP2 | |
| SCHEMBL31519881 | 0.92 | PRMT3 (0.58) | PRMT3EP300PRMT6PRMT1ENPP2 | |
| SCHEMBL10611423 | 0.86 | PRMT1 (0.67) | PRMT3EP300PRMT6PRMT1ENPP2 | |
| SCHEMBL29660882 | 0.86 | PRMT1 (0.67) | PRMT3EP300PRMT6PRMT1ENPP2 | |
| SCHEMBL10611415 | 0.86 | PRMT1 (0.67) | PRMT3EP300PRMT6PRMT1ENPP2 | |
| SCHEMBL13880639 | 0.83 | PRMT1 (0.59) | PRMT3EP300PRMT6PRMT1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373868-A4 | IMPROVED AFFINITY MATRICES WITH ENHANCED VISIBILITY FOR MOLECULAR PULL-DOWN AND IMMUNOPRECIPITATION APPLICATIONS | SIGMA ALDRICH CO (US) | 2006-11-29 | — | — | EP | claimed |
| US-6887377-B2 | Affinity matrices with enhanced visibility for molecular pull-down and immunoprecipitation applications | SIGMA-ALDRICH CO. (US) | 2005-05-03 | — | — | US | claimed |
| EP-1373868-A1 | IMPROVED AFFINITY MATRICES WITH ENHANCED VISIBILITY FOR MOLECULAR PULL-DOWN AND IMMUNOPRECIPITATION APPLICATIONS | Sigma-Aldrich Co. (US) | 2004-01-02 | — | — | EP | claimed |
| US-20020108908-A1 | Affinity matrices with enhanced visibility for molecular pull-down and immunoprecipitation applications | SIGMA-ALDRICH CO. | 2002-08-15 | — | — | US | claimed |
| WO-2002061406-A1 | IMPROVED AFFINITY MATRICES WITH ENHANCED VISIBILITY FOR MOLECULAR PULL-DOWN AND IMMUNOPRECIPITATION APPLICATIONS | SIGMA-ALDRICH CO. (US) | 2002-08-08 | — | — | WO | claimed |
| EP-1373868-B1 | IMPROVED AFFINITY MATRICES WITH ENHANCED VISIBILITY FOR MOLECULAR PULL-DOWN AND IMMUNOPRECIPITATION APPLICATIONS | SIGMA ALDRICH CO LLC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-20090098074-A1 | Keratin-Binding Effector Molecules Containing Reactive Dyes | BASF SE (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090098074-A1 | Keratin-Binding Effector Molecules Containing Reactive Dyes | BASF SE (DE) | 2009-04-16 | — | — | US | disclosed |
| US-7438806-B2 | Affinity matrices with enhanced visibility for molecular pull-down and immunoprecipitation applications | SIGMA-ALDRICH CO. (US) | 2008-10-21 | — | — | US | disclosed |
| US-20070048800-A1 | Affinity matrices with enhanced visibility for molecular pull-down and immunoprecipitation applications | SIGMA-ALDRICH CO. (US) | 2007-03-01 | — | — | US | disclosed |
| US-7163633-B2 | Affinity matrices with enhanced visibility for molecular pull-down and immunoprecipitation applications | SIGMA-ALDRICH CO. (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1373868-A4 | IMPROVED AFFINITY MATRICES WITH ENHANCED VISIBILITY FOR MOLECULAR PULL-DOWN AND IMMUNOPRECIPITATION APPLICATIONS | SIGMA ALDRICH CO (US) | 2006-11-29 | — | — | EP | disclosed |
| US-6887377-B2 | Affinity matrices with enhanced visibility for molecular pull-down and immunoprecipitation applications | SIGMA-ALDRICH CO. (US) | 2005-05-03 | — | — | US | disclosed |
| US-20050079554-A1 | Affinity matrices with enhanced visibility for molecular pull-down and immunoprecipitation applications | SIGMA-ALDRICH CO. | 2005-04-14 | — | — | US | disclosed |
| EP-1373868-A1 | IMPROVED AFFINITY MATRICES WITH ENHANCED VISIBILITY FOR MOLECULAR PULL-DOWN AND IMMUNOPRECIPITATION APPLICATIONS | Sigma-Aldrich Co. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20020108908-A1 | Affinity matrices with enhanced visibility for molecular pull-down and immunoprecipitation applications | SIGMA-ALDRICH CO. | 2002-08-15 | — | — | US | disclosed |
| WO-2002061406-A1 | IMPROVED AFFINITY MATRICES WITH ENHANCED VISIBILITY FOR MOLECULAR PULL-DOWN AND IMMUNOPRECIPITATION APPLICATIONS | SIGMA-ALDRICH CO. (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098074-A1 | Keratin-Binding Effector Molecules Containing Reactive Dyes | KRT18, KLK3, KLKB1 | PRMT3 1298/4885EP300 3664/4885PRMT6 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.